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hydrostatic pressurization of cartilage. The tissue’s ﬁxed negative charge
density is determined by the glycosaminoglycan (GAG) chains in the PGs.
Healthy cartilage has a (physiological) tonicity of 350–480 mOsm, while
the tonicity of the ECM in OA stage-dependently approaches plasma
values (i.e. ~280mOsm). Culturing chondrocytes under tonic conditions
improves their phenotype. Calcineurin inhibition promotes chondrogenic
marker expression and is known to regulate cellular hypertrophy in other
tissues.
We aimed to elucidate if modulating calcineurin activity under
physiological conditions can improve the chondrogenic phenotype while
preventing hypertrophic differentiation of human chondrocytes in vitro.
Methods: Human articular chondrocytes (HACs) were isolated and
cultured in DMEM of 380 and 280mOsm (control) with or without
addition of calcineurin inhibitor FK506 in passage 1 (P1) and
P2. Chondrogenic (COL types -II, -IX, -XI; aggrecan, matrilin 1),
(pre-)hypertrophic (Ihh, COL-X, MMP-13; alkaline phosphatase, ALP;
VEGF), catabolic (MMPs, ADAMTS’) and osteogenic (COL-I, Runx2, SPP-1)
markers were evaluated on mRNA and protein level in 2D monolayer
cultures and 3D microtissues. Treatment was also evaluated employing
non-arthritic chondrocytes and cartilage explants as was the contribution
of TGFb/BMP signaling.
Results: Compared to the 280mOsm control, culturing HACs at
physiological tonicity (380mOsm) showed a general beneﬁcial trend
in chondrogenic marker expression, with increased mRNA levels of
COL2, AGC and SOX9 and suppression of unwanted COL1. Inhibiting
calcineurin activity using FK506 further improved the anabolic effects of
physiological tonicity (e.g. COL2 50-fold, n = 6; veriﬁed on protein level in
2D and 3D), but decreased tonicity-induced expression of collagenases
and aggrecanases. The tonicity-induced expression of hypertrophy
markers COL-X, MMP-13 and ALPL was selectively, dose-dependently
inhibited by FK506 (n =6), which also reduced ALPL and MMP13 activity.
Similar effects were found in non-arthritic chondrocytes and cartilage
explants (n = 3 patients ea.). TGFb superfamily members were selectively
up-regulated by tonicity, while FK506 seems to antagonize BMP-induced
hypertrophic differentiation.
Conclusions: Physiological tonicity largely improves chondrogenic
marker expression in primary human chondrocytes in vitro, but
up-regulates several hypertrophic markers. Under these conditions,
inhibition of calcineurin activity selectively suppresses catabolic and
hypertrophic markers, which is at least partially mediated by TGFb
superfamily signaling. Our ﬁnding may open new venues in the
treatment of OA.
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Purpose: AMP-activated protein kinase (AMPK) is a super-regulator
of energy homeostasis and cellular metabolism, and increases muscle
stamina. In addition, AMPK suppresses inﬂammation, partly by inhibiting
NF-úB activation. Recently, reduced AMPK activity was discovered to
develop in human knee OA chondrocytes and in cultured chondrocytes
treated with the inﬂammatory cytokines IL-1b and TNFa. AMPK activators
suppress cartilage matrix degradation induced by IL-1b and TNFa in
vitro. LKB1 is the major upstream activating kinase of AMPK, and
PP2C is a protein phosphatase that can dephosphorylate AMPKa.
Here, we examined the roles of LKB1 and PP2C in regulation of
AMPK in articular chondrocytes. SIRT1, a NAD-dependent histone/protein
deacetylase, is another nutrient-sensing metabolic regulator. Decreased
SIRT1 expression is observed in human OA cartilage, and SIRT1 activity
is shown to be chondroprotective in vitro. Since SIRT1 has been
demonstrated to modulate LKB1, we also tested if SIRT1 regulates AMPK
activity in articular chondrocytes.
Methods: Expression and phosphorylation of LKB1 were examined in
human knee cartilage sections from different donors without (grade
I) and with OA (grades II-IV). We also studied normal aging mouse
knee cartilage sections (with an age range of 3, 6, 12 and 24 months).
Expression of PP2C was assessed in normal articular chondrocytes in
response to IL-1b and TNFa. LKB1 and SIRT1 were either overexpressed
or knocked down in human chondrocytes via transfection with their
cDNAs and siRNAs, respectively. Resveratrol was used to active Sirt1.
Status of acetylation of LKB1, phosphorylation of LKB1 and AMPKa were
examined, and we assayed pro-catabolic responses including nitric oxide
(NO) generation, and expression of MMP-3 in response to IL-1b and
TNFa.
Results: Decreased expression and phosphorylation of LKB1, and
concurrently AMPKa, were observed in human knee OA cartilages
compared with normal cartilage. In addition, there was age-related
loss of expression and phosphorylation of LKB1 in the aging
mouse knee cartilages. IL-1b and TNFa induced PP2Ca expression
in chondrocytes. Knockdown of LKB1 in chondrocytes resulted in
attenuated phosphorylation of AMPKa and increased NO generation (by
50% and 80%, respectively, P < 0.05) and augmented MMP-3 release in
response to IL-1b and TNFa. Activation of SIRT1 by resveratrol resulted
in de-acetylation of LKB1 and increased phosphorylation (activation
responses) of both LKB1 and AMPKa. Overexpression of SIRT1 and LKB1
increased phosphorylation of LKB1, and prevented de-phosphorylation
of AMPKa induced by IL-1b and TNFa. Last, knockdown of SIRT1 led
to decreased phosphorylation of AMPKa and increased chondrocyte
catabolic responses to IL-1b and TNFa.
Conclusions: AMPK activity is promoted by LKB1 and inhibited by PP2C
in articular chondrocytes. SIRT1 plays a central role in this functional
loop by activating AMPK, mediated by SIRT1-induced LKB1 activation in
chondrocytes. Maintenance of AMPK activity by stimulation of the LKB1
and/or inhibition of PP2C in articular chondrocytes has novel therapeutic
potential to prevent cartilage matrix degradation, and thereby to slow
progression of OA.
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Purpose: The pathogenesis of osteoarthritis (OA) affects both the bone
and cartilage compartment. Parathyroid hormone (PTH) is a well-known
modulator of calcium homeostasis and exerts both anabolic and catabolic
effects on bone related to treatment of osteoporosis. PTH acts on
osteoblasts, initiating the G-coupled receptor pathway through cAMP.
Recently, cAMP has been shown to be of major importance for the
chondrocyte phenotype. We set out to investigate the effect of PTH in
relation to OA. The expression of PTH receptor 1 (PTH1R) and the effects
of PTH on human osteoarthritic cartilage were investigated in vitro. The
effect on cartilage degradation was investigated in a rodent model of
accelerated bone and cartilage loss.
Methods: In vitro: The expression of the PTH1R was investigated
in human OA chondrocytes by qPCR, the PTH1R protein by
immunohistochemistry (IHC) in full thickness cartilage explants, and
functionality by cAMP ELISA. Human OA chondrocytes were isolated by
enzyme treatment and subsequently maintained serum-free for 1 hour
in the presence of 100mM IBMX (a phosphordiesterase inhibitor), and
subsequently stimulated with PTH(1–84) 1 nM-100nM + IBMX for 30
min and the intracellular levels of cAMP were quantiﬁed by ELISA.
Direct anabolic effects of PTH were studied in vitro by stimulation of
human OA articular cartilage explants with doses of 1 nM-100 mM
PTH. The cultures were maintained for 17 days and pulsed by 5mCi
35Sulphate. Anabolic effects on proteoglycan formation were evaluated by
incorporation of 35Sulphate, followed by liquid scintillation counting in
the extracted cartilage proteoglycan. Effects on collagen type II formation
were investigated in the conditioned medium from the explants cultures
by quantiﬁcation of neo-epitopes of the N-terminal propeptide of
collagen type II by ELISA (PIINP). In vivo: Thirty 5-month old female rats
were subjected to either sham or ovariectomy (OVX), and administered
either vehicle or 30mg/kg hPTH (1–34) by s.c. injection for 5 weeks,
n = 10. Serum levels of osteocalcin and collagen type II degradation neo-
epitopes (CTX-II) were measured by ELISA.
Results: Human articular chondrocytes expressed the PTH receptor
1 as detected by qPCR and IHC. PTH stimulation induced increased
levels of intracellular cAMP (P < 0.003) compared with vehicle control.
Additionally, PTH increased the release of PIINP from OA articular
cartilage explants cultures by two-fold. Furthermore, 10nM PTH
increased incorporation of 35sulphate by 40% (P = 0.002). In the in vivo
study of rodents subjected to OVX and treated by s.c injections of PTH, the
